Product Name: A-1210477

Request A-1210477

CAT#: A-9036


  Synonym:A-1210477,

A-1210477 Chemical Structure
A-1210477 chemical structure


5 stars, based on 8355 reviews
IUPAC/Chemical name:

Price of A-1210477

We offer a substantial discount on larger orders,
please inquire via sales@activebiochem.com
or Fax: 1-201-884-1288 (USA Fax#)


Biological Activity
A-1210477 is a potent and selective MCL-1 inhibitor which binds to MCL-1 selectively and with sufficient affinity to disrupt MCL-1-BIM complexes in living cells. A-1210477 induces the hallmarks of intrinsic apoptosis and demonstrates single agent killing of multiple myeloma and non-small cell lung cancer cell lines.
Technical Data
M.Wt: 941.19
Solubility: DMSO
CAS#:
Chemical Formula:C46H55N7O7S.2.5HCl
M.Wt.: 941.19
Purity: >99%
Storage Conditions: 2ºC to 8 ºC, or -20ºC for 3 years.

Reference
Cell Death Dis. 2015 Jan 15;6:e1590. doi: 10.1038/cddis.2014.561.
Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
The anti-apoptotic protein MCL-1 is a key regulator of cancer cell survival and a known resistance factor for small-molecule BCL-2 family inhibitors such as ABT-263 (navitoclax), making it an attractive therapeutic target. However, directly inhibiting this target requires the disruption of high-affinity protein-protein interactions, and therefore designing small molecules potent enough to inhibit MCL-1 in cells has proven extremely challenging. Here, we describe a series of indole-2-carboxylic acids, exemplified by the compound A-1210477, that bind to MCL-1 selectively and with sufficient affinity to disrupt MCL-1-BIM complexes in living cells. A-1210477 induces the hallmarks of intrinsic apoptosis and demonstrates single agent killing of multiple myeloma and non-small cell lung cancer cell lines demonstrated to be MCL-1 dependent by BH3 profiling or siRNA rescue experiments. As predicted, A-1210477 synergizes with the BCL-2/BCL-XL inhibitor navitoclax to kill a variety of cancer cell lines. This work represents the first description of small-molecule MCL-1 inhibitors with sufficient potency to induce clear on-target cellular activity. It also demonstrates the utility of these molecules as chemical tools for dissecting the basic biology of MCL-1 and the promise of small-molecule MCL-1 inhibitors as potential therapeutics for the treatment of cancer.



Purchase(buy) A-1210477 at Active Biochem and the United State(U.S.), Germany, Japan, France,United Kingdom(UK),Switzerland, Australia distributors.